CANCER DIAGNOSTICS

assay

Determination of Cancer Aggressiveness

The blood test can also provide information about the aggressiveness of the cancer independent of imaging. The analysis requires high quality images of the cancer associated cells.

The features indicating aggressive cancers are listed below.  The features are independent of type of cancer or stage.

Publications

Major Features That Predict Poor Prognosis:

  • CTC number > 5
  • CTC in mitosis
  • CAML size ≥ 50 µm
  • Micronuclei (MN) in CAMLs
  • Extracellular Vesicles (EVs) budding from CAMLs
  • Debris in CAMLs
  • Micronuclei (MN) in CAMLs
  • DAPI size of CAMLs >465 µm2
  • CTC clusters
  • Presence of other types of tumor-macrophage hybrid cells (TMHCs) besides CAMLs

Patients have longer PFS and OS even if they have CTCs and CAMLs, but not those 10 features.

A blood test for companion diagnostics is simpler and cheaper than tissue biopsy.  CAMLs contain tumor markers. 

CAMLs are ideal for companion diagnostics because they are found in

  • All cancers

  • All stages of cancer

More than 30 drug targets have been developed by CreatvBio.  Some examples are:

  • PD-L1, PD-L2

  • HER2

  • CCR5

  • CXCR4

  • VEGFR1-2

Companion/Complementary Diagnostics

Many cancer drugs target specific markers on the surface of the tumor.  If the tumor does not express the marker, then the patient is not expected to respond to the drug.  The test to determine effective use of the therapeutic drug for a patient is called companion diagnostics.

We can develop a simple blood test for companion diagnostics for the drug.

Publications